Jae Seung Yang, Ph.D. is Head of Clinical Immunology at IVI. His research interest focuses on the development, standardization, and validation of assays for measuring vaccine-induced immune responses, particularly against enteric and respiratory pathogens, in clinical trials conducted by IVI or in partnership with other organizations in developing countries.
Jae Seung received his Ph.D. in Biology from Korea Advanced Institute of Science and Technology, and he joined IVI in 2004. He has developed a miniaturized ELISPOT assay which can be used in young infants for detecting vaccine-specific antibody-secreting cells in small (< 1ml) volumes of blood and developed functional assays for cholera and typhoid vaccines. His laboratory has also contributed to the WHO-prequalification of two oral cholera vaccines (Shanchol™, Sanofi Pasteur and Euvichol®, EuBiologics) by assessing immune responses in several clinical studies.
His team participated in NIBSC/WHO collaborative studies funded by the Bill & Melinda Gates Foundation, a multi-national project involving seven laboratories from six countries, to establish an international standard serum and harmonization of the assay for typhoid Vi-conjugate vaccines (TCVs). IVI’s in-house assay has been demonstrated to be the best non-commercial alternative and was established as international standard assay for TCVs. His team supported clinical studies from phase 1 to 3 for TCV (SKYTyphoid, SK bioscience) which was licensed by the Korean regulatory authority and is undergoing the WHO PQ process. Recently, he established systems serology to seek significant distinct biomarkers/immune correlates of protection in infectious diseases.